Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs EDP 322 (Primary)
- Indications Bacterial infections; Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 09 Oct 2009 New trial record